Wall Street analysts predict that Cambrex Co. (NYSE:CBM) will report sales of $110.80 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cambrex’s earnings. The highest sales estimate is $115.50 million and the lowest is $106.10 million. Cambrex reported sales of $105.01 million during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The firm is scheduled to issue its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Cambrex will report full year sales of $110.80 million for the current year. For the next year, analysts anticipate that the company will report sales of $573.53 million per share, with estimates ranging from $559.60 million to $587.45 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Cambrex.
Cambrex (NYSE:CBM) last posted its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The firm had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. During the same period in the previous year, the firm earned $1.23 earnings per share. The company’s revenue was up 2.5% on a year-over-year basis.
A number of research firms have issued reports on CBM. Longbow Research cut Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. Zacks Investment Research cut Cambrex from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. Finally, William Blair began coverage on Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $60.00.
NYSE:CBM traded down $0.15 on Friday, reaching $53.65. The company’s stock had a trading volume of 325,595 shares, compared to its average volume of 218,782. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95. The stock has a market cap of $1,762.24, a price-to-earnings ratio of 16.92, a PEG ratio of 1.27 and a beta of 2.32.
Hedge funds have recently bought and sold shares of the company. Financial Gravity Companies Inc. acquired a new position in shares of Cambrex during the fourth quarter worth about $166,000. Visionary Asset Management Inc. acquired a new position in shares of Cambrex during the third quarter worth about $201,000. Trexquant Investment LP acquired a new position in shares of Cambrex during the third quarter worth about $209,000. Sei Investments Co. boosted its position in shares of Cambrex by 3,120.9% during the third quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock worth $228,000 after buying an additional 4,026 shares during the period. Finally, Elkfork Partners LLC acquired a new position in shares of Cambrex during the fourth quarter worth about $202,000.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/cambrex-co-cbm-expected-to-post-quarterly-sales-of-110-80-million-2.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Get a free copy of the Zacks research report on Cambrex (CBM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.